-
公开(公告)号：US09365522B2
公开(公告)日：2016-06-14
申请号：US14633936
申请日：2015-02-27
申请人： AMGEN INC. , TEIJIN PHARMA LIMITED
发明人： Hilary Plake Beck , Shon Keith Booker , Howard Bregman , Victor J. Cee , Nagasree Chakka , Timothy D. Cushing , Oleg Epstein , Brian M. Fox , Stephanie Geuns-Meyer , Xiaolin Hao , Kenta Hibiya , Jun Hirata , Zihao Hua , Jason Human , Shinji Kakuda , Patricia Lopez , Ryota Nakajima , Kazuhisa Okada , Steven H. Olson , Hiroyuki Oono , Lewis D. Pennington , Kosuke Sasaki , Keiko Shimada , Youngsook Shin , Ryan D. White , Ryan P. Wurz , Shuyan Yi , Xiao Mei Zheng
IPC分类号： C07D231/14 , C07D403/12 , C07D401/14 , C07D405/14 , C07D401/12 , C07D405/12 , C07D409/12 , C07D417/14 , C07D493/08 , C07D413/12 , A61K31/4155 , A61K31/44 , A61K31/4427 , A61K31/422
CPC分类号： C07D231/14 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/12 , C07D417/14 , C07D493/08
摘要： The present invention relates to a novel compound having a function of inhibiting RORγ activity. The present invention also relates to pharmaceutical composition comprising the compound, a use of the compound in treating or preventing autoimmune diseases, inflammatory diseases, metabolic diseases, or cancer diseases.
摘要翻译： 本发明涉及具有抑制RORγ活性的新型化合物。 本发明还涉及包含该化合物的药物组合物，该化合物在治疗或预防自身免疫疾病，炎性疾病，代谢疾病或癌症疾病中的用途。
-
公开(公告)号：US20150266824A1
公开(公告)日：2015-09-24
申请号：US14633936
申请日：2015-02-27
申请人： AMGEN INC. , Teijin Pharma Limited
发明人： Hilary Plake Beck , Shon Keith Booker , Howard Bregman , Victor J. Cee , Nagasree Chakka , Timothy D. Cushing , Oleg Epstein , Brian M. Fox , Stephanie Geuns-Meyer , Xiaolin Hao , Kenta Hibiya , Jun Kirata , Zihao Hua , Jason Human , Shinji Kakuda , Patricia Lopez , Ryota Nakajima , Kazuhisa Okada , Steven H. Olson , Hiroyuki Oono , Lewis D. Pennington , Kosuke Sasaki , Keiko Shimada , Youngsook Shin , Ryan D. White , Ryan P. Wurz , Shuyan Yi , Xiao Mei Zheng
IPC分类号： C07D231/14 , C07D409/12 , C07D413/12 , C07D405/14 , C07D401/14 , C07D493/08 , C07D401/12 , C07D403/12
CPC分类号： C07D231/14 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/12 , C07D417/14 , C07D493/08
摘要： The present invention relates to a novel compound having a function of inhibiting RORγ activity. The present invention also relates to pharmaceutical composition comprising the compound, a use of the compound in treating or preventing autoimmune diseases, inflammatory diseases, metabolic diseases, or cancer diseases.
摘要翻译： 本发明涉及具有抑制RORγ活性的新型化合物。 本发明还涉及包含该化合物的药物组合物，该化合物在治疗或预防自身免疫疾病，炎性疾病，代谢疾病或癌症疾病中的用途。
-
公开(公告)号：US11332459B2
公开(公告)日：2022-05-17
申请号：US16754349
申请日：2018-10-18
发明人： Michael D. Bartberger , Nagasree Chakka , Hua Gao , Angel Guzman-Perez , Daniel B. Horne , Zihao Hua , Madeleine Kieffer , Daniel C. H. Lin , Benjamin Charles Milgram , Jane Panteleev , Laurie Schenkel , John Stellwagen , Matthew Weiss , Ryan D. White , Wei Zhao
IPC分类号： C07D401/14 , A61K31/4545 , C07D401/04 , C07D403/04 , C07D413/14 , C07D471/04 , C07D471/10 , C07D498/04
摘要： The present invention relates to inhibitors of Transient Receptor Potential Channel 6 (TRPC6) protein activity. The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.
-
4.发明申请公开(公告)号：US20150057271A1
公开(公告)日：2015-02-26
申请号：US14377478
申请日：2013-02-12
申请人： AMGEN INC.
发明人： Christiane Boezio , Alessandro Boezio , Howard Bregman , Nagasree Chakka , James R. Coats , Katrina Woodin Copeland , Erin F. Dimauro , Thomas Dineen , Hua Gao , Daniel La , Isaac E. Marx , Hanh Nho Nguyen , Emily Anne Peterson , Matthew Weiss
IPC分类号： C07D417/14 , C07D471/04 , C07D413/14 , C07D417/12 , C07D413/12
CPC分类号： C07D417/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D471/04
摘要： The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders. Also provided are pharmaceutical compositions containing compounds of the present invention.
摘要翻译： 本发明提供式I化合物或其药学上可接受的盐，其是电压门控钠通道的抑制剂，特别是Nav 1.7。 该化合物可用于治疗可通过抑制钠通道（例如疼痛障碍）治疗的疾病。 还提供含有本发明化合物的药物组合物。
-
公开(公告)号：US09663508B2
公开(公告)日：2017-05-30
申请号：US15026740
申请日：2014-10-01
申请人： AMGEN INC.
发明人： Howard Bregman , Nagasree Chakka , Erin F. Dimauro , Hua Gao , Hakan Gunaydin , Hongbing Huang , Philip R. Olivieri , Laurie Schenkel , Matthew Weiss
IPC分类号： C07D417/12 , C07D213/64 , C07D213/26 , C07D213/643 , C07D213/70 , C07D401/04 , C07D405/12
CPC分类号： C07D417/12 , C07D213/26 , C07D213/64 , C07D213/643 , C07D213/70 , C07D401/04 , C07D405/12
摘要： The present invention provides compounds of Formula (Ia), and pharmaceutically acceptable salts thereof. The compounds are useful as inhibitors of voltage-gated sodium channels, in particular Nav 1.7. as described in the specification. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders. Also provided are pharmaceutical compositions containing compounds of the present invention, as well as intermediates and processes useful for making the compounds.
-
公开(公告)号：US09340549B2
公开(公告)日：2016-05-17
申请号：US14383432
申请日：2013-03-01
申请人： AMGEN INC.
发明人： Howard Bregman , John L. Buchanan , Nagasree Chakka , Erin F. Dimauro , Hakan Gunaydin , Angel Guzman-Perez , Zihao Hua , Hongbing Huang , Xin Huang , Matthew W. Martin , Vinod F. Patel
IPC分类号： C07D413/14 , C07D487/04 , C07D413/08 , C07D413/12 , C07D417/12 , C07D417/14 , C07D471/04 , C07D473/00 , C07D263/34 , C07D519/00 , C07D413/10
CPC分类号： C07D487/04 , C07D263/34 , C07D413/08 , C07D413/10 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D471/04 , C07D473/00 , C07D519/00
摘要： Compounds of Formula (I) and Formula (II) are useful inhibitors of tankyrase. Compounds of Formula (I) and Formula (II) have the following structure: where the definitions of the variables are provided herein.
摘要翻译： 式（I）和式（II）的化合物是阻聚酶的有用抑制剂。 式（I）和式（II）的化合物具有以下结构：其中在此提供变量的定义。
-
公开(公告)号：US20150045368A1
公开(公告)日：2015-02-12
申请号：US14383432
申请日：2013-03-01
申请人： AMGEN INC.
发明人： Howard Bregman , John L. Buchanan , Nagasree Chakka , Erin F. Dimauro , Hakan Gunaydin , Angel Guzman-Perez , Zihao Hua , Hongbing Huang , Xin Huang , Matthew W. Martin , Vinod F. Patel
IPC分类号： C07D487/04 , C07D519/00 , C07D413/14 , C07D413/10 , C07D471/04 , C07D413/12
CPC分类号： C07D487/04 , C07D263/34 , C07D413/08 , C07D413/10 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D471/04 , C07D473/00 , C07D519/00
摘要： Compounds of Formula (I) and Formula (II) are useful inhibitors of tankyrase. Compounds of Formula (I) and Formula (II) have the following structure: where the definitions of the variables are provided herein.
摘要翻译： 式（I）和式（II）的化合物是阻聚酶的有用抑制剂。 式（I）和式（II）的化合物具有以下结构：其中在此提供变量的定义。
-
公开(公告)号：US09505749B2
公开(公告)日：2016-11-29
申请号：US14423078
申请日：2013-08-27
申请人： AMGEN INC.
发明人： Howard Bregman , John L. Buchanan , Nagasree Chakka , Erin F. Dimauro , Hakan Gunaydin , Angel Guzman-Perez , Zihao Hua , Xin Huang
IPC分类号： C07D471/02 , C07D403/12 , C07D401/14 , C07D413/14 , C07D401/12 , C07D239/90 , C07D239/95 , C07D413/12 , C07D417/12 , C07D417/14 , C07D471/04
CPC分类号： C07D471/02 , C07D239/90 , C07D239/95 , C07D401/12 , C07D401/14 , C07D403/12 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D471/04
摘要： Compounds of Formula I are useful inhibitors of tankyrase. Compounds of Formula I have the following structure: where the definitions of the variables are provided herein.
-
9.发明授权公开(公告)号：US09346798B2
公开(公告)日：2016-05-24
申请号：US14377478
申请日：2013-02-12
申请人： AMGEN INC.
发明人： Christiane Boezio , Alessandro Boezio , Howard Bregman , Nagasree Chakka , James R. Coats , Katrina Woodin Copeland , Erin F. Dimauro , Thomas Dineen , Hua Gao , Daniel La , Isaac E. Marx , Hanh Nho Nguyen , Emily Anne Peterson , Matthew Weiss
IPC分类号： C07D413/12 , C07D417/12 , C07D413/14 , C07D471/04 , C07D417/14
CPC分类号： C07D417/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D471/04
摘要： The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders. Also provided are pharmaceutical compositions containing compounds of the present invention.
摘要翻译： 本发明提供式I化合物或其药学上可接受的盐，其是电压门控钠通道的抑制剂，特别是Nav 1.7。 该化合物可用于治疗可通过抑制钠通道（例如疼痛障碍）治疗的疾病。 还提供含有本发明化合物的药物组合物。
-
公开(公告)号：US20150225396A1
公开(公告)日：2015-08-13
申请号：US14423078
申请日：2013-08-27
申请人： AMGEN INC.
发明人： Howard Bregman , John L. Buchanan , Nagasree Chakka , Erin F. Dimauro , Hakan Gunaydin , Angel Guzman-Perez , Zihao Hua , Xin Huang
IPC分类号： C07D471/02 , C07D413/14 , C07D401/14 , C07D239/95 , C07D401/12 , C07D239/90 , C07D417/12 , C07D413/12 , C07D417/14
CPC分类号： C07D471/02 , C07D239/90 , C07D239/95 , C07D401/12 , C07D401/14 , C07D403/12 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D471/04
摘要： Compounds of Formula I are useful inhibitors of tankyrase. Compounds of Formula I have the following structure: where the definitions of the variables are provided herein.
摘要翻译： 式I化合物是阻聚酶的有用抑制剂。 式I的化合物具有以下结构：其中本文提供变量的定义。
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.044 秒)
